ReProtect  Products to protect reproductive health

Welcome
About ReProtect
Contact ReProtect
News
Glossary
Site Map

 

Investor Information

ReProtect's Mission is to reduce unwanted pregnancy and sexually transmitted diseases, including HIV/AIDS, by providing the most effective and innovative products to women and men throughout the world.

ReProtect, Inc. is a privately held company founded in 1993 by three faculty members of Johns Hopkins University. ReProtect is located in Baltimore, Maryland and has a renewable research agreement with the Johns Hopkins University. Qualified investors interested in receiving an information package, please contact Kristen Khanna at (410) 516-7260, cell (202) 489-6402, or kkhanna@reprotect.com.

Management

Richard A. Cone, Ph.D. - Chair of the Board
Richard Cone is a cofounder of ReProtect.  He is a Professor in the Departments of Biophysics and Biology at Johns Hopkins University. Dr. Cone trained at the Massachusetts Institute of Technology, received his doctoral degree from the University of Chicago, and was previously on the faculty at Harvard University. He is a co-inventor with Drs. Whaley and Moench of the technology in ReProtect’s portfolio of intellectual property.

Thomas R. Moench, M.D. - President, Chief Operating Officer
Thomas Moench, a cofounder of ReProtect, trained as a physician at the Johns Hopkins University School of Medicine and served on the faculty of the Department of Medicine, Division of Infectious Diseases, for ten years prior to becoming a founding member of ReProtect. Dr. Moench’s research interests have included animal models of HIV transmission, and the pathophysiology of sexually transmitted diseases.  Dr. Moench devotes full-time effort to ReProtect, overseeing pre-clinical and clinical research. He is a co-inventor of BufferGel and Duet.

Kevin J. Whaley, Ph.D. - V.P. Strategic Development
Kevin Whaley, a cofounder of ReProtect, is a reproductive physiologist trained at the Medical College of Ohio.  He completed his post-doctoral research on male contraception at the Indian Institute of Science and at the Oregon Primate Research Center.  Dr. Whaley’s research interests include the use of antibodies for prophylaxis and treatment of disease including STDs.  A founding member of ReProtect, he is a co-inventor of methods using antibodies for contraception and has co-founded Mapp Biopharmaceutical, Inc. (San Diego, CA) to commercialize  novel antibody technology for reproductive health. He is a co-founder of the Alliance for Microbicide Development, and a leading activist for microbicide development.

Kristen V. Khanna, Ph.D., M.B.A. -  Administrative Director
Kristen Khanna completed her post-doctoral training in the Department of Molecular Microbiology and Immunology at the Johns Hopkins School of Public Health, and her M.B.A. at Johns Hopkins University School of Professional Studies in Business and Education. She is founder and President of Laboratory Link, LLC, a consulting practice assisting in efforts to commercialize scientific discoveries, particularly in the areas of women’s health and wellness.



Top

Business

 
Last updated 11/24/08  |  Legal Information  |  Copyright ReProtect Inc., 2003-2008